No Data
No Data
Capbio (300639): Clear base and go to battle lightly
Key investment performance overview: In 2023, the company achieved operating income of 1,104 billion yuan, a year-on-year decrease of 80.27%; net profit to mother was 140 million yuan, a year-on-year decrease of -91.86%; net profit after deducting non-return to mother was 1.1 billion yuan
Capbio (300639.SZ): Net loss of 14.354,800 yuan in the first quarter
On April 26, Ge Longhui (300639.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 183 million yuan, a year-on-year decrease of 39.39%; net profit attributable to shareholders of listed companies - 14.3548 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 15.953 million yuan; basic earnings per share - 0.02 yuan.
Capbio (300639.SZ): 2023 net profit of 140 million yuan, plans to distribute 10 to 0.65 yuan
On April 23, Ge Longhui (300639.SZ) announced its 2023 annual report. Operating revenue for the reporting period was 1.04 billion yuan, down 80.27% year on year; net profit attributable to shareholders of listed companies was 140 million yuan, down 91.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 113 million yuan, down 93.47% year on year; it plans to distribute a cash dividend of 0.65 yuan (tax included) for every 10 shares to all shareholders.
Capbio (300639.SZ): No nuclear radiation-related tests on humans or saltwater fish and shrimp
Gelonghui, April 8, 丨 Kepu Biotech (300639.SZ) said on the investor interactive platform that the company is a leading integrated provider of molecular diagnostic products and services. It independently develops, produces and sells a series of testing products and related molecular diagnostic instruments in the field of infectious and hereditary diseases, including tumor testing, maternal and child health, birth defects, infectious diseases, individualized medication, etc. Related products are widely used in hospital clinical diagnosis, large-scale seawater population screening, public health prevention and control. There is no testing related to human or fish nuclear radiation.
Guangdong Hybribio Biotech, Subsidiary Get Patent From Brazil for Isolation Method
Guangdong Hybribio Biotech (SHE:300639) and its subsidiary, Guangzhou Hybribio Biotech, received an invention patent certificate from Brazil's national industrial property authority for one of its inv
Capbio (300639.SZ): Obtained a Brazilian invention patent certificate
Gelonghui, March 21丨Capbio (300639.SZ) announced that recently, Guangdong Kepu Biotechnology Co., Ltd. and its wholly-owned subsidiary Guangzhou Kaipu Pharmaceutical Technology Co., Ltd. obtained an invention patent certificate issued by Brazil's National Industrial Property Office as a method for isolating placental trophoblasts from pregnant women's cervical desquamation cells.
No Data